Mounting evidence indicates that the presence of measurable (“minimal”) residual disease
(MRD), defined as posttherapy persistence of leukemic cells at levels below morphologic …

The introduction of imatinib mesylate (IM) has revolutionized the treatment of chronic
myeloid leukemia (CML). Although experience is too limited to permit evidence-based …

Background Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has
resulted in high rates of complete cytogenetic response and progression-free survival …

Dasatinib is a highly potent BCR-ABL inhibitor with established efficacy and safety in
imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 …

This study examines the prognostic significance of early molecular response using an
expanded dataset in chronic myeloid leukemia patients enrolled in the International …

There is considerable interest in developing techniques to detect and/or quantify remaining
leukaemia cells termed measurable or, less precisely, minimal residual disease (MRD) in …

Imatinib is a molecularly targeted therapy that inhibits the oncogenic fusion protein BCR-
ABL, the tyrosine kinase involved in the pathogenesis of chronic myelogenous leukemia …

Imatinib mesylate (STI571) is effective in chronic phase chronic myelogenous leukemia
(CML). However, most patients treated with 400 mg imatinib daily have variable levels of …

BACKGROUND The advent of imatinib has considerably changed the treatment of chronic
myeloid leukemia (CML). Early studies demonstrated high rates of hematologic and …

Patients with CLL responding to initial chemotherapy with fludarabine alone (F) or in
combination with cyclophosphamide (FC) were randomized for treatment with alemtuzumab …